{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:29:15Z","timestamp":1790753355368,"version":"4.1.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009591","name":"Ministerium f\u00fcr Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen","doi-asserted-by":"publisher","award":["2015-2021"],"award-info":[{"award-number":["2015-2021"]}],"id":[{"id":"10.13039\/501100009591","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"DOI":"10.3389\/fped.2018.00065","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T12:45:11Z","timestamp":1521722711000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Cystic Kidney Diseases From the Adult Nephrologist\u2019s Point of View"],"prefix":"10.3389","volume":"6","author":[{"given":"Roman-Ulrich","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Benzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1111\/j.1523-1755.2005.09403.x","article-title":"The epidemiology of chronic kidney disease","volume":"67","author":"Atkins","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"B2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/ckj\/sfw047","article-title":"Chronic kidney disease in children","volume":"9","author":"Becherucci","year":"2016","journal-title":"Clin Kidney J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/gb-2014-15-1-r15","article-title":"Differential protein occupancy profiling of the mRNA transcriptome","volume":"15","author":"Schueler","year":"2014","journal-title":"Genome Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1056\/NEJMra1010172","article-title":"Ciliopathies","volume":"364","author":"Hildebrandt","year":"2011","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ng.3871","article-title":"Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease","volume":"49","author":"Lu","year":"2017","journal-title":"Nat Genet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"a028191","DOI":"10.1101\/cshperspect.a028191","article-title":"Ciliopathies","volume":"9","author":"Braun","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneph.2015.205","article-title":"Exploring the genetic basis of early-onset chronic kidney disease","volume":"12","author":"Vivante","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/MNH.0b013e3283520f17","article-title":"Clinical spectrum and pathogenesis of nephronophthisis","volume":"21","author":"Benzing","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/ndt\/gfs551","article-title":"Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany","volume":"28","author":"Neumann","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/1471-2369-15-182","article-title":"Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study","volume":"15","author":"McGovern","year":"2014","journal-title":"BMC Nephrol"},{"key":"B13","first-page":"128","article-title":"Bilateral polycystic disease of the kidneys; a follow-up of 284 patients and their families","volume":"4","author":"Dalgaard","year":"1957","journal-title":"Dan Med Bull"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1093\/ndt\/gfw240","article-title":"Prevalence of autosomal dominant polycystic kidney disease in the European Union","volume":"32","author":"Willey","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(10)60236-X","article-title":"Genetic kidney diseases","volume":"375","author":"Hildebrandt","year":"2010","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1136\/archdischild-2015-310221","article-title":"Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis","volume":"101","author":"Marlais","year":"2016","journal-title":"Arch Dis Child"},{"key":"B17","doi-asserted-by":"publisher","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival \u2013 an analysis of data from the ERA-EDTA registry","volume":"29","author":"Spithoven","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B18","unstructured":"Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents with ADPKD (Autosomal Dominant Polycystic Kidney Disease)2017"},{"key":"B19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/nrneph.2014.173","article-title":"An approach to cystic kidney diseases: the clinician\u2019s view","volume":"10","author":"Kurschat","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nrurol.2015.206","article-title":"Molecular genetics and clinical features of Birt-Hogg-Dub\u00e9 syndrome","volume":"12","author":"Schmidt","year":"2015","journal-title":"Nat Rev Urol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1681\/ASN.2015050544","article-title":"Hepatocyte nuclear factor 1\u03b2-associated kidney disease: more than renal cysts and diabetes","volume":"27","author":"Verhave","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0272-6386(12)70338-4","article-title":"An ultrasound renal cyst prevalence survey: specificity data for inherited renal cystic diseases","volume":"22","author":"Ravine","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1681\/ASN.2014030297","article-title":"Imaging-based diagnosis of autosomal dominant polycystic kidney disease","volume":"26","author":"Pei","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1681\/ASN.2016090938","article-title":"Polycystic kidney disease without an apparent family history","volume":"28","author":"Iliuta","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/ckj\/sfx071","article-title":"Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan","volume":"11","author":"M\u00fcller","year":"2018","journal-title":"Clin Kidney J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(03)13860-3","article-title":"Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment","volume":"362","author":"Wiebers","year":"2003","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1681\/ASN.V131269","article-title":"Management of cerebral aneurysms in autosomal dominant polycystic kidney disease","volume":"13","author":"Pirson","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B31","first-page":"69","article-title":"Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment","volume":"3","author":"Halvorson","year":"2010","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/ndt\/gft437","article-title":"Extra-renal manifestations of ADPKD: considerations for routine screening and management","volume":"29","author":"Luciano","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B33","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1053\/j.seminoncol.2016.09.001","article-title":"Genetic predisposition to kidney cancer","volume":"43","author":"Schmidt","year":"2016","journal-title":"Semin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fped.2017.00124","article-title":"Diagnosis and management of hepatobiliary complications in autosomal recessive polycystic kidney disease","volume":"5","author":"Wehrman","year":"2017","journal-title":"Front Pediatr"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1681\/ASN.2006121344","article-title":"Nephronophthisis-associated ciliopathies","volume":"18","author":"Hildebrandt","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s00467-008-0840-z","article-title":"Nephronophthisis","volume":"24","author":"Salomon","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/jmedgenet-2015-103304","article-title":"Large-scale targeted sequencing comparison highlights extreme genetic heterogeneity in nephronophthisis-related ciliopathies","volume":"53","author":"Schueler","year":"2016","journal-title":"J Med Genet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2215\/CJN.04180609","article-title":"A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease","volume":"5","author":"Barash","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000463063","article-title":"Polycystic kidney disease and the vasopressin pathway","volume":"70","author":"van Gastel","year":"2017","journal-title":"Ann Nutr Metab"},{"key":"B40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2215\/CJN.03950510","article-title":"Water prescription in autosomal dominant polycystic kidney disease: a pilot study","volume":"6","author":"Wang","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e018794","DOI":"10.1136\/bmjopen-2017-018794","article-title":"Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD)","volume":"8","author":"Wong","year":"2018","journal-title":"BMJ Open"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.kint.2016.10.018","article-title":"Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease","volume":"91","author":"Torres","year":"2017","journal-title":"Kidney Int"},{"key":"B45","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/ki.2015.28","article-title":"Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management \u2013 a KDIGO consensus report","volume":"88","author":"Eckardt","year":"2015","journal-title":"Kidney Int"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1053\/jhep.1997.v26.pm0009362373","article-title":"Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease","volume":"26","author":"Sherstha","year":"1997","journal-title":"Hepatology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.semnephrol.2015.10.015","article-title":"KHA-CARI autosomal dominant polycystic kidney disease guideline: management of polycystic liver disease","volume":"35","author":"Savige","year":"2015","journal-title":"Semin Nephrol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-018-0470-x","article-title":"Nutritional therapy in autosomal dominant polycystic kidney disease","author":"Di Iorio","year":"2018","journal-title":"J Nephrol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"B52","unstructured":"The German ADPKD Tolvaptan Treatment Registry2017"},{"key":"B53","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B54","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","article-title":"Polycystic kidney disease","volume":"60","author":"Harris","year":"2009","journal-title":"Annu Rev Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B56","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1","volume":"21","author":"Shillingford","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2174\/1573402113666170427142815","article-title":"Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials","volume":"13","author":"Brosnahan","year":"2017","journal-title":"Curr Hypertens Rev"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1681\/ASN.2016111232","article-title":"Bosutinib versus placebo for autosomal dominant polycystic kidney disease","volume":"28","author":"Tesar","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2174\/1389450116666150427161743","article-title":"Therapeutic targets in polycystic liver disease","volume":"18","author":"Masyuk","year":"2017","journal-title":"Curr Drug Targets"},{"key":"B64","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1053\/j.gastro.2011.11.036","article-title":"Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease","volume":"142","author":"Masyuk","year":"2012","journal-title":"Gastroenterology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40620-017-0395-9","article-title":"Defective glycolysis and the use of 2-deoxy-D-glucose in polycystic kidney disease: from animal models to humans","volume":"30","author":"Magistroni","year":"2017","journal-title":"J Nephrol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1038\/s41598-017-07300-x","article-title":"Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency","volume":"7","author":"Chang","year":"2017","journal-title":"Sci Rep"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1172\/JCI64401","article-title":"Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease","volume":"123","author":"Zhou","year":"2013","journal-title":"J Clin Invest"},{"key":"B68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model","volume":"26","author":"Hopp","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/hmg\/ddw376","article-title":"Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model","volume":"26","author":"Zhu","year":"2017","journal-title":"Hum Mol Genet"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fped.2018.00065\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T18:39:59Z","timestamp":1660675199000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fped.2018.00065\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":69,"alternative-id":["10.3389\/fped.2018.00065"],"URL":"https:\/\/doi.org\/10.3389\/fped.2018.00065","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]},"article-number":"65"}}